Clinical trial

iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

NCT05413369

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-07-07

PhasePHASE3

Study timeline

Study start (actual)2022-07-07Date precision: day

Registry last updated2025-09-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetes Mellitusunresolved

Interventions

Insulin glargine/LixisenatideDRUG

IDegAspDRUG

MetforminDRUG · verified · RxNorm: metformin

SGLT2 inhibitorDRUG

Sponsors & collaborators

Sanofilead sponsor

Mapped research locations

ShanghaiChina4 BeijingChina3 NanjingChina3 GuangzhouChina2 TianjinChina2 ChengduChina2 HangzhouChina1 ChongqingChina1 ChangshaChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05413369 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.